<DOC>
	<DOCNO>NCT02307864</DOCNO>
	<brief_summary>The purpose study assess effect multiple dos immediate release ( IR ) formulation tramadol hydrochloride ( HCl ) therapeutic supratherapeutic level healthy adult participant electrocardiogram ( ECG ) QT interval correct heart rate ( QTc ) .</brief_summary>
	<brief_title>Study Evaluate Effects Tramadol Hydrochloride Cardiac Repolarization Healthy Participants</brief_title>
	<detailed_description>This randomize ( study medication assign chance ) , double-blind ( neither physician participant know treatment participant receives ) , 4-way crossover ( method use switch participant one treatment arm another ) , placebo- positive-controlled ( experimental treatment procedure compare inactive substance standard treatment procedure ) , single site , multiple dose study . The study 3 phase : Screening Phase ( 35 day ) ; Double-blind Treatment Phase ( 4 treatment period washout period 7 15 day ) ; Post-treatment Phase ( Day 5 Period 4 time early withdrawal ) . All eligible participant receive 4 treatment : tramadol HCl therapeutic dose 400 milligram per day ( mg/day ) , tramadol HCl supratherapeutic dose 600 mg/day , placebo , positive control moxifloxacin 400 mg ; treatment period per assign treatment sequence . The total duration participant 's participation maximum 100 day . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Tramadol</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Woman participant childbearing potential , must negative serum betahuman chorionic gonadotropin pregnancy test Screening ; negative urine pregnancy test Day 1 treatment period Standard electroencephalogram ( EEG ) normal , assessed neurologist . The EEG perform basic condition hyperventilation intermittent photic stimulation Screening Body mass index ( BMI ; weight [ kilogram ] /height [ square meter ] ) 18 30 kilogram per square meter ( inclusive ) , body weight less 50 kilogram Screening Blood pressure 90 140 millimeter mercury ( mm Hg ) systolic ( inclusive ) high 90 mm Hg diastolic An average triplicate 12lead electrocardiogram ( ECG ) recording ( perform semisupine position ) , complete within 4 minute total , consistent normal cardiac conduction function Screening , include : 1 Sinus rhythm heart rate 40 100 beat per minute ( inclusive ) ; 2 QTc interval 350 450 millisecond ( inclusive ) ; 3 QRS interval le 110 millisecond ; 4 PR interval le 200 millisecond ; 5 ECG morphology consistent healthy cardiac conduction function Personal family history epileptic seizure convulsion ( genetic idiopathic seizure ) , suffer head trauma loss consciousness , central nervous system infection , loss consciousness unknown origin History additional risk factor torsades de pointes ( TdP ) presence family history short QT syndrome , long QT syndrome , sudden unexplained death young age ( less equal 40 year ) , drown sudden infant death syndrome first degree relative ( , biological parent , sibling , child ) Clinically significant abnormal value hematology , clinical chemistry , urinalysis Screening first dose study drug Day 1 treatment period assess Investigator . Note participant serum potassium , magnesium , calcium level outside local laboratory 's reference range exclude Clinically significant abnormal physical examination vital sign Screening first dose study drug Day 1 treatment period assess Investigator History drug alcohol abuse within 5 year Screening positive test result ( ) alcohol drug abuse ( barbiturate , opiate , cocaine , cannabinoids , amphetamine , hallucinogen , benzodiazepine ) Screening Day 1 treatment period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Healthy</keyword>
	<keyword>QT interval</keyword>
	<keyword>QTc interval</keyword>
	<keyword>Electrocardiogram</keyword>
	<keyword>Tramadol hydrochloride</keyword>
	<keyword>Moxifloxacin</keyword>
	<keyword>Placebo</keyword>
</DOC>